CGA M-21
- Guideline for Determining Pharmacovigilance Reporting Requirements in North America (for the U.S. & Reference for Canada)
- standard by Compressed Gas Association, 11/01/2017
- Category: CGA
$27.00
$14.00
This publication provides guidance for pharmacovigilance reporting to FDA and acts as a reference for Health Canada pharmacovigilance reporting. This guidance is intended to aid companies that market medical gases classified as drugs in the United States or Canada in setting up a pharmacovigilance (drugs) reporting system that satisfies local and regional regulatory requirements, bearing in mind any global requirements when applicable.
Although both reporting for drugs and devices is required, this publication only addresses medical gases classified as drugs (pharmacovigilance) and does not address reporting requirements for gases or medical gas equipment classified as medical devices (materiovigilance).
In the United States, this publication should be used as a guideline for companies to comply with 21 CFR Part 314. In Canada this publication may only be used for a reference.
Although both reporting for drugs and devices is required, this publication only addresses medical gases classified as drugs (pharmacovigilance) and does not address reporting requirements for gases or medical gas equipment classified as medical devices (materiovigilance).
In the United States, this publication should be used as a guideline for companies to comply with 21 CFR Part 314. In Canada this publication may only be used for a reference.
PDF
All of our standards document are available in PDF (Portable Document Format), an electronic, downloadable format.You will be able to download the file in your account downloads.
Multi-User Access
After purchasing, you have the ability to assign each license to a specific user.
Printable
At any time, you are permitted to make printed copies for your and your members' reference use.
